{"id":3174,"date":"2018-09-13T17:57:08","date_gmt":"2018-09-13T12:27:08","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3174"},"modified":"2023-04-04T11:59:14","modified_gmt":"2023-04-04T06:29:14","slug":"the-business-cocktails","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails","title":{"rendered":"Atreca secured $125M; OncoResponse bags $40M; Kodiak Sciences\u2019s IPO; Biodesy contemplates $20M"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Atreca secured USD 125 Million when solid tumor trial comes into picture<\/strong><\/p>\n<p style=\"text-align: justify;\">California based company, <strong>Atreca<\/strong> has bagged <strong>USD 125 million<\/strong> to establish its <strong>R&amp;D<\/strong> activities. As the company gears up, the <strong>series C\u00a0round<\/strong>\u00a0enters, to move its <strong>lead solid tumor<\/strong> <strong>drug<\/strong> into the clinic.\u00a0 Atreca has set up its credentials through VC rounds that added <strong>USD 91 million<\/strong> to its funds and engrossed the backing of investors like <strong>GlaxoSmithKline<\/strong> and the <strong>Bill &amp; Melinda Gates Foundation<\/strong>. GSK and the Gates Foundation commenced working with Atreca too.<\/p>\n<p style=\"text-align: justify;\"><strong>OncoResponse bags USD 40 Million for cancer patient-sourced antibodies<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>OncoResponse<\/strong> has secured <strong>USD 40 million<\/strong> in <strong>second-round financing<\/strong> to develop drugs based on antibodies taken from cancer survivors. The cash will be designated to get five programs from antibody-mining R&amp;D of OncoResponse that is presently concentrated on melanoma, non-small cell lung cancer, <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-hormone-refractory-prostate-cancer-market\">prostate cancer<\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/gastric-cancer-market\">gastric cancer<\/a> and chronic myeloid leukemia, into human testing. The company bagged <strong>USD 9.5 million<\/strong> in its <strong>series A<\/strong> round in 2015.<\/p>\n<p style=\"text-align: justify;\"><strong>Kodiak Sciences gets ready for USD 100 Million IPO to progress Age-related Macular Degeneration (AMD) drug<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Kodiak Sciences<\/strong>, California-based company, has filed to set up <strong>USD100 million<\/strong> in its <strong>IPO<\/strong> that will bolster the <strong>phase<\/strong> <strong>2<\/strong> development of <strong>anti-VEGF drug<\/strong> for <strong>eye diseases<\/strong>. It is now being tried in multiple trials in <a href=\"https:\/\/www.delveinsight.com\/report-store\/age-related-macular-degeneration-amd-market\"><strong>age-related macular degeneration (AMD)<\/strong><\/a> and <a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-retinopathy-market\"><strong>diabetic retinopathy<\/strong><\/a>.\u00a0The treatment is injected squarely into the eyes. The company is targeting to progress this with its prime drug, <strong>KSI-301<\/strong>.<\/p>\n<p style=\"text-align: justify;\"><strong>Biodesy contemplates USD 20 Million in VC funding<\/strong><\/p>\n<p style=\"text-align: justify;\">The molecule-monitoring company, <strong>Biodesy<\/strong> declared that it has brought in <strong>USD 20 million<\/strong> in <strong>venture capital<\/strong> and chosen a new CEO. The company has been developing high-throughput systems that identify structural shifts in proteins and other biological molecules in real time, gauging how shape changes can affect function, pathway regulation and responses to drugs and novel candidates.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Atreca secured USD 125 Million when solid tumor trial comes into picture California based company, Atreca has bagged USD 125 million to establish its R&amp;D activities. As the company gears up, the series C\u00a0round\u00a0enters, to move its lead solid tumor drug into the clinic.\u00a0 Atreca has set up its credentials through VC rounds that added [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3157,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":1,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17671,1809,1802,1805,985,1728,1806,1804,1807,1808,1810,1803],"industry":[17225],"therapeutic_areas":[17228,17244],"class_list":["post-3174","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-age-relateda-macular-degeneration","tag-atreca","tag-biodesy","tag-diabetic-retinopathy","tag-glaxosmithkline","tag-ipo","tag-kodiak-sciences","tag-ksi-301","tag-oncoresponse","tag-second-round-financing","tag-the-bill-melinda-gates-foundation","tag-venture-capital","industry-pharmaceutical","therapeutic_areas-oncology","therapeutic_areas-ophthalmology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Atreca secured $125M; OncoResponse bags $40M<\/title>\n<meta name=\"description\" content=\"The molecule-monitoring company, Biodesy declared that it has brought in USD 20 million in venture capital and............\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Atreca secured $125M; OncoResponse bags $40M\" \/>\n<meta property=\"og:description\" content=\"The molecule-monitoring company, Biodesy declared that it has brought in USD 20 million in venture capital and............\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-09-13T12:27:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-04T06:29:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09023959\/pharma-licensing-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"620\" \/>\n\t<meta property=\"og:image:height\" content=\"410\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Atreca secured $125M; OncoResponse bags $40M","description":"The molecule-monitoring company, Biodesy declared that it has brought in USD 20 million in venture capital and............","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails","og_locale":"en_US","og_type":"article","og_title":"Atreca secured $125M; OncoResponse bags $40M","og_description":"The molecule-monitoring company, Biodesy declared that it has brought in USD 20 million in venture capital and............","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-09-13T12:27:08+00:00","article_modified_time":"2023-04-04T06:29:14+00:00","og_image":[{"width":620,"height":410,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09023959\/pharma-licensing-1.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails","name":"Atreca secured $125M; OncoResponse bags $40M","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09023959\/pharma-licensing-1.jpg","datePublished":"2018-09-13T12:27:08+00:00","dateModified":"2023-04-04T06:29:14+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The molecule-monitoring company, Biodesy declared that it has brought in USD 20 million in venture capital and............","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktails"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09023959\/pharma-licensing-1.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09023959\/pharma-licensing-1.jpg","width":620,"height":410,"caption":"Johnson & Johnson"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09023959\/pharma-licensing-1-300x198.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Age-related\u00c2 macular degeneration<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Atreca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Biodesy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">diabetic retinopathy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GlaxoSmithKline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">IPO<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Kodiak Sciences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">KSI-301<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">OncoResponse<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">second-round financing<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">the Bill Melinda Gates Foundation<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">venture capital<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Age-related\u00c2 macular degeneration<\/span>","<span class=\"advgb-post-tax-term\">Atreca<\/span>","<span class=\"advgb-post-tax-term\">Biodesy<\/span>","<span class=\"advgb-post-tax-term\">diabetic retinopathy<\/span>","<span class=\"advgb-post-tax-term\">GlaxoSmithKline<\/span>","<span class=\"advgb-post-tax-term\">IPO<\/span>","<span class=\"advgb-post-tax-term\">Kodiak Sciences<\/span>","<span class=\"advgb-post-tax-term\">KSI-301<\/span>","<span class=\"advgb-post-tax-term\">OncoResponse<\/span>","<span class=\"advgb-post-tax-term\">second-round financing<\/span>","<span class=\"advgb-post-tax-term\">the Bill Melinda Gates Foundation<\/span>","<span class=\"advgb-post-tax-term\">venture capital<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Sep 13, 2018","modified":"Updated on Apr 4, 2023"},"absolute_dates_time":{"created":"Posted on Sep 13, 2018 5:57 pm","modified":"Updated on Apr 4, 2023 11:59 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3174","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3174"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3174\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3157"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3174"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3174"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3174"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3174"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3174"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}